Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
Rhea-AI Summary
Nurix Therapeutics (Nasdaq: NRIX) will host a live webcast on Monday, December 8, 2025 at 8:15 p.m. ET to review new and updated clinical data from the ongoing Phase 1a/1b trial of BTK degrader bexobrutideg (NX-5948) and provide a corporate update.
Presenters include investigator Alvaro Alencar, M.D., CEO Arthur T. Sands, M.D., Ph.D., and CMO Paula G. O’Connor, M.D.. The webcast and archived replay will be available in the Investors section of the Nurix website under Events and Presentations.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NRIX declined 4.36%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.4% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $76M from the company's valuation, bringing the market cap to $1.66B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NRIX was up 0.31% with mixed peer moves in Biotechnology: RIGL and RLAY rose 2.69% and 2.37%, while AVBP, DAWN, and PRME declined between -0.69% and -1.39%, suggesting a stock-specific setup into the webcast.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | ASH Phase 1 data | Positive | +18.7% | Detailed positive Phase 1 bexobrutideg efficacy and safety data at ASH. |
| Dec 01 | Webcast announcement | Neutral | -4.4% | Announcement of webcast to review new Phase 1a/1b bexobrutideg data. |
| Nov 25 | Conference participation | Neutral | -0.9% | Participation in Piper Sandler healthcare conference with webcast access. |
| Nov 10 | Board appointment | Positive | -0.5% | Appointment of oncology-focused leader Roger Dansey to board of directors. |
| Nov 07 | NX-1607 trial data | Positive | -1.7% | Positive translational data from Phase 1a trial of CBL-B inhibitor NX-1607. |
Clinical and scientific updates have often produced muted or negative next-day moves, with one strong positive reaction when detailed bexobrutideg efficacy data were presented.
Over the last six months, Nurix has repeatedly highlighted progress across its degrader pipeline. Bexobrutideg clinical data in CLL and WM, including high response rates and durable outcomes, and multiple conference presentations have been central themes. A notable ASH Phase 1 readout on Dec 8, 2025 coincided with a 18.68% move, contrasting with modest declines after earlier clinical and conference updates. Governance moves, such as appointing Roger Dansey to the board, and a sizable equity offering in October 2025 have also shaped the company’s trajectory into this webcast-focused announcement.
Market Pulse Summary
This announcement outlines a scheduled webcast on December 8, 2025 to review new Phase 1a/1b data for BTK degrader bexobrutideg in relapsed or refractory CLL and WM and to provide a corporate update. It continues a pattern of frequent scientific communication and major-meeting participation for Nurix’s degrader pipeline. Investors may focus on the depth of efficacy and safety data shared, how it compares with prior bexobrutideg readouts, and implications for future trial design and timelines.
Key Terms
bruton’s tyrosine kinase medical
btk degrader medical
phase 1a/1b medical
chronic lymphocytic leukemia medical
waldenström macroglobulinemia medical
webcast technical
AI-generated analysis. Not financial advice.
SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that the company will host a live webcast on Monday, December 8, 2025, at 8:15 p.m. ET, to review new and updated clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton’s tyrosine kinase (BTK) degrader program, bexobrutideg (NX-5948), and provide a corporate update.
The webcast will feature a presentation by guest speaker and clinical study investigator Alvaro Alencar, M.D., Associate Professor of Clinical Medicine and Chief Medical Director, University of Miami Sylvester Cancer Center, who will present clinical data from the ongoing Phase 1a/1b trial of bexobrutideg in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM). Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, and Paula G. O’Connor, M.D., chief medical officer of Nurix, will discuss bexobrutideg’s differentiating features, Nurix’s clinical development strategy, and provide a corporate update.
Webcast Details
Date and time: Monday, December 8, 2025, 8:15 p.m. ET
Access Details: The live webcast and archived replay will be available in the Investors section of the Nurix website under Events and Presentations.
About Bexobrutideg (NX-5948)
Bexobrutideg is an investigational, orally bioavailable, brain penetrant, highly selective, small molecule degrader of BTK currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia. Nurix also continues enrollment in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) of bexobrutideg in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trials can be accessed at clinicaltrials.gov.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi and a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding Nurix’s intention to present updated data from the clinical trials of bexobrutideg at the 67th American Society of Hematology Annual Meeting, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended August 31, 2025, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Contacts:
Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Kris Fortner
Nurix Therapeutics
Kfortner@nurixtx.com
FAQ
When is Nurix (NRIX) scheduled to webcast updated NX-5948 data?
What clinical data will Nurix (NRIX) review in the December 8, 2025 webcast?
Who will present NX-5948 clinical results on the Nurix (NRIX) webcast?
Where can investors watch the Nurix (NRIX) NX-5948 webcast replay?
What patient populations are included in the NX-5948 Phase 1a/1b trial discussed by Nurix (NRIX)?
Will the Nurix (NRIX) webcast include a corporate update in addition to clinical data?
